Study of PF-07248144 in Advanced or Metastatic Solid Tumors

PHASE1RECRUITING

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with either fulvestrant or letrozole + palbociclib or with PF-07220060 + fulvestrant.

info
Simpliy with AI

Study details:

Study has two parts, Part 1 (dose escalation) and Part 2 (dose expansion). Part 1 is divided into Parts 1A, 1B, 1C and 1D and Part 2 is divided into Parts 2A, 2B and 2D. In Part 1A, single escalating doses of PF-07248144 alone will be administered to determine the maximum tolerable dose (MTD) and select the recommended dose for expansion (RDE).

In Part 1B,1C and 1D, PF-07248144 will be administered in combination with either fulvestrant (Part 1B); palbociclib + letrozole (Part 1C) or PF-07220060+fulvestrant (Part 1D). . After the determination of the monotherapy RDE in Part 1A, PF-07248144 will be evaluated in a dose expansion cohort as a monotherapy in Part 2A.

After determination of the combination RDE from Part 1B, PF-07248144 in combination with fulvestrant, PF-07248144 will be evaluated in a combination dose expansion with fulvestrant in Part 2B. In Part 1C, PF-07248144 in combination with letrozole + palbociclib will be evaluated for dose finding to determine the MTD and RDE for this combination. After determination of the triple combination RDE from Part 1D, PF-07248144 in combination with PF-07220060 + fulvestrant will be evaluated in a combination dose-expansion cohort, Part 2D.

info
Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  • Disease Characteristics - Breast, Prostate, and Lung Cancer
  • Part 1A (Monotherapy Dose Escalation) Histological or cytological diagnosis of locally advanced or metastatic ER+HER2- breast cancer, CRPC, or NSCLC that is intolerant or resistant to standard therapy or for which no standard therapy is available.
  • Part 1B, Part 1C and Part 1D (Combination Dose Escalation) Histological or cytological diagnosis of locally advanced or metastatic ER+HER2- breast cancer. Participants must have progressed after at least 1 prior line of treatment with an endocrine therapy and CDK4/6 inhibitor in the advanced or metastatic setting.
  • Part 2A (ER+HER2- breast cancer 2L+, monotherapy) Histological or cytological diagnosis of locally advanced or metastatic ER+HER2- breast cancer. Participants must have progressed after at least 1 prior line of CDK4/6 inhibitor and 1 line of endocrine therapy.
  • Part 2B (ER+HER2- breast cancer 2-4L, combination with fulvestrant) Histological or cytological diagnosis of advanced or metastatic ER+HER2- breast cancer. Participants must have progressive disease after at least 1 prior line of a CDK4/6 inhibitor and at least 1 prior line of endocrine therapy. Participants must not have received more than 3 prior lines of systemic therapies including up to 1 line of cytotoxic chemotherapy for visceral disease in advanced or metastatic setting; Participants may have but are not required to have prior treatment with fulvestrant.
  • Part 2D (ER+HER2- breast cancer 2-4L, combination with PF-07220060 (CDK4i) and fulvestrant): Histological or cytological diagnosis of advanced or metastatic ER+HER2- breast cancer. Participants must have progressive disease after at least 1 prior line of a CDK4/6 inhibitor and at least 1 prior line of endocrine therapy.
  • Participants must have not received more than 3 lines of systemic therapies including up to 1 line of cytotoxic chemotherapy for visceral disease in advanced or metastatic setting; Participants may have but are not required to have prior treatment with fulvestrant.
  • Participants with ER+HER2- advanced or metastatic breast cancer must have documentation of ER-positive tumor (≥1% positive stained cells) based on most recent tumor biopsy utilizing an assay consistent with local standards.
  • Participants with ER+HER2- advanced or metastatic breast cancer must have documentation of HER2-negative tumor: HER2-negative tumor is determined as immunohistochemistry score 0/1+ or negative by in situ hybridization (FISH/CISH/SISH/DISH) defined as a HER2/CEP17 ratio <2 or for single probe assessment a HER2 copy number <4.
  • Female participants with ER+HER2- advanced or metastatic breast cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause by treatment with the approved LHRH agonist such as goserelin, leuprolide or equivalent agents to induce chemical menopause.
  • Female participants with ER+HER2- advanced or metastatic breast cancer of nonchildbearing potential must meet at least 1 criteria of achieving postmenopausal status.
  • Participants must have at least 1 measurable lesion as defined by RECIST version 1.1 that has not been previously irradiated.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status PS 0 or 1
  • Female or male patients aged ≥ 18 years (Japan ≥ 20 years) (South Korea ≥ 19 years).
  • Adequate renal, liver, and bone marrow function.
  • Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for adverse events (AEs) not constituting a safety risk by investigator judgment.
  • Exclusion criteria

  • Unmanageable ascites (limited medical treatment to control ascites is permitted, but all participants with ascites require review by sponsor's medical monitor).
  • Participants with any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
  • Major surgery, radiation therapy, or systemic anti-cancer therapy within 3 weeks prior to study entry.
  • Prior irradiation to >25% of the bone marrow.
  • ECG clinically relevant abnormalities (eg, QTc >470 msec, complete LBBB, second/third degree AV block, ST elevation or EKG changes suggesting myocardial infarction or active myocardia ischemia).
  • Therapeutic anticoagulation. However, low molecular weight heparin is allowed. Vitamin K antagonists or factor Xa inhibitors may be allowed following discussion with the Sponsor.
  • Known or suspected hypersensitivity or severe allergy to active ingredient/excipients of PF-07248144.
  • Active inflammatory GI disease, refractory and unresolved chronic diarrhea or previous gastric resection, lap band surgery or other GI conditions and surgeries that may significantly alter the absorption of PF-07248144 tablets. Gastroesophageal reflux disease under treatment is allowed.
  • Pregnant or breastfeeding female participants.
  • info
    Simplify with AI

    Eligibility

    Age eligible for study : 18 and older

    Healthy volunteers accepted : No

    Gender eligible for study: All

    Things to know

    Study dates

    Study start: 2020-11-16

    Primary completion: 2025-05-09

    Study completion finish: 2026-11-08

    study type

    Study type

    TREATMENT

    phase

    Phase

      PHASE1

    trial

    Trial ID

    NCT04606446

    Intervention or treatment

    DRUG: PF-07248144

    DRUG: Fulvestrant

    DRUG: Letrozole

    DRUG: Palbociclib

    DRUG: PF-07220060

    Conditions

    • Locally Advanced or Metastatic ER+ HER2- Breast Cancer
    • Locally Advanced or Metastatic Castration-resistant Prostate Cancer
    • Locally Advanced or Metastatic Non-small Cell Lung Cancer
    Image related to Locally Advanced or Metastatic ER+ HER2- Breast Cancer
    • Condition: Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer and more

    • DRUG: PF-07248144 and other drugs

    • Camperdown, New South Wales, Australia and more

    • Sponsor: Pfizer

    Find a site

    Closest Location:

    Chris O'Brien Lifehouse

    Research sites nearby

    Select from list below to view details:

    • Chris O'Brien Lifehouse

      Camperdown, New South Wales, Australia

    • Cancer Research South Australia

      Adelaide, South Australia, Australia

    • Peter MacCallum Cancer Centre

      Melbourne, Victoria, Australia

    • Royal Melbourne Hospital

      Parkville, Victoria, Australia

    Loading...

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    How is the study designed?

    Participant Group/ArmIntervention/Treatment
    EXPERIMENTAL: 1A Monotherapy Dose Escalation
    • PF-07248144 Monotherapy Escalation
    DRUG: PF-07248144
    • KAT6 Inhibitor
    EXPERIMENTAL: 1B Combination Dose Escalation
    • PF-07248144 with Fulvestrant Combination Dose Escalation
    DRUG: PF-07248144
    • KAT6 Inhibitor
    EXPERIMENTAL: 1C Combination Dose Escalation
    • PF-07248144 with Letrozole + Palbociclib Combination Dose Escalation
    DRUG: PF-07248144
    • KAT6 Inhibitor
    EXPERIMENTAL: 2A Monotherapy Dose Expansion Arm
    • PF-07248144 Monotherapy Dose Expansion
    DRUG: PF-07248144
    • KAT6 Inhibitor
    EXPERIMENTAL: 2B Combination Dose Expansion Arm
    • PF-07248144 with Fulvestrant Dose Expansion
    DRUG: PF-07248144
    • KAT6 Inhibitor
    EXPERIMENTAL: 1D Combination Dose Escalation
    • PF-07248144 with PF-07220060 +Fulvestrant
    DRUG: PF-07248144
    • KAT6 Inhibitor
    EXPERIMENTAL: 2D Combination Dose Expansion Arm
    • PF-07248144 with PF-07220060 +Fulvestrant Dose Expansion
    DRUG: PF-07248144
    • KAT6 Inhibitor
    EXPERIMENTAL: China Monotherapy Dose Expansion
    • PF-07248144 Monotherapy Dose Expansion
    DRUG: PF-07248144
    • KAT6 Inhibitor

    What is the study measuring?

    Primary outcome

    Primary Outcome MeasurePrimary Outcome DescriptionPrimary Outcome Time Frame
    Number of participants with dose-limiting toxicities in the Dose Escalation Arms.Dose-limiting toxicities (DLTs)Up to 29 days
    Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Escalation Arms.Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study therapy.Up to 24 months
    Safety and Tolerability through monitoring of laboratory assessments for participants enrolled in the Dose Escalation Arms.Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.Up to 24 months
    Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Expansion ArmsAdverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study therapy.Up to 24 months
    Safety and Tolerability through monitoring of laboratory assessments for participants enroled in the Dose Expansion ArmsLaboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.Up to 24 months

    Secondary outcome

    Secondary Outcome MeasureSecondary Outcome DescriptionSecondary Outcome Time Frame
    Single Dose: Maximum Observed Concentration (Cmax) in the Dose Escalation and Dose Finding ArmsPharmacokinetic (PK) assessments for PF-07248144 and PF-07220060 (Part 1D)Up to 24 months
    Single Dose: Time to Maximum concentration (Tmax) in the Dose Escalation and Dose Finding ArmsPharmacokinetic (PK) assessments for PF-07248144 and PF-07220060 (Part 1D)Up to 24 months
    Single Dose: AUC from time zero to time of last measurable concentration (AUClast) in the Dose Escalation and Dose Finding ArmsPharmacokinetic (PK) assessments for PF-07248144 and PF-07220060 (Part 1D)Up to 24 months
    Single and Multiple Dose: Terminal Elimination half-life (t1/2) in the Dose Escalation and Dose Finding ArmsPharmacokinetic (PK) assessments for PF-07248144 and PF-07220060 (Part 1D)Up to 24 months
    Multiple Dose: Steady-State Cmax (Cmax,ss) in the Dose Escalation and Dose Finding ArmsPharmacokinetic (PK) assessments for PF-07248144 and PF-07220060 (Part 1D)Up to 24 months
    Multiple Dose: Steady-state Tmax (Tmax,ss) in the Dose Escalation and Dose Finding ArmsPharmacokinetic (PK) assessments for PF-07248144 and PF-07220060 (Part 1D)Up to 24 months
    Multiple Dose: Steady state AUC during a dosage interval (τ) (AUCτ,ss) in the Dose Escalation and Dose Finding ArmsPharmacokinetic (PK) assessments for PF-07248144 and PF-07220060 (Part 1D)Up to 24 months
    Multiple Dose: Steady-state Cmin (Cmin,ss) in the Dose Escalation and Dose Finding Arms.Pharmacokinetic (PK) assessments for PF-07248144 and PF-07220060 (Part 1D)Up to 24 months
    Multiple Dose: Steady-state apparent total clearance (CLss/F) in the Dose Escalation and Dose Finding Arms.Pharmacokinetic (PK) assessments for PF-07248144 and PF-07220060 (Part 1D)Up to 24 months
    Palbociclib trough concentrations at steady instate (Cmin,ss) in the 1C combination dose finding arm.Pharmacokinetic (PK) assessment for palbociclib exposure.Up to 24 months
    Best Overall Response (BOR) in participants in the Dose Expansion ArmsNot SpecifiedUp to 24 months
    Duration of Response (DOR) in participants enrolled in the Dose Expansion ArmsNot SpecifiedUp to 24 months
    Peak concentrations of PF-07248144 and PF-07220060 (Part 2D) for selected cycles in the Dose Expansion ArmsPharmacokinetic (PK) assessment for PF-07248144 and PF-07220060 (Part 2D)Up to 24 months
    Trough concentrations of PF-07248144 for selected cycles in the Dose Expansion ArmsPharmacokinetic (PK) assessment for PF-07248144 and PF-07220060 (Part 2D)Up to 24 months
    Maximum Observed Concentration (Cmax) in the participants in the food effect subset in monotherapy dose expansion armThe effect of food on the PK of PF-07248144.Cycle 1 Day -7 and Cycle 1 Day 1 (each cycle is 28 days)
    Time to Maximum concentration (Tmax) in the participants in the food effect subset in monotherapy dose expansion armThe effect of food on the PK of PF-07248144.Cycle 1 Day -7 and Cycle 1 Day 1 (each cycle is 28 days)
    AUC from time zero to time of last measurable concentration (AUClast) in the participants in the food effect subset in monotherapy dose expansion armThe effect of food on the PK of PF 07248144.Cycle 1 Day -7 and Cycle 1 Day 1 (each cycle is 28 days)
    Amount of PF-07248144 excreted in urine relative to dose administered (%) in a sub-set of participants in monotherapy dose expansion arm.Evaluate urine pharmacokinetic (PK) of PF-07248144.Up to 24 months
    Renal clearance (CLr) in a sub-set of participants in monotherapy dose expansion armEvaluate urine pharmacokinetic (PK) of PF-07248144.Up to 24 months
    Progression Free Survival (PFS) observed in participants in the Dose Expansion ArmsNot SpecifiedUp to 24 months
    Time to Progression (TTP) observed in participants enrolled in the Dose Expansion ArmsNot SpecifiedUp to 24 months
    Overall survival (OS) observed in participants enrolled in Dose Expansion ArmsNot SpecifiedUp to 24 months
    Best Overall Response (BOR) observed in participants in the dose expansion armsNot SpecifiedUp to 24 months
    Duration of Response (DOR) observed in participants in the dose expansion armsNot Specifiedup to 24 months
    Clinical Benefit Rate (CBR) observed in participants in the Dose Expansion ArmsNot Specifiedup to 24 months

    Frequently Asked Questions

    Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

    No questions submitted. Be the first to ask a question!

    You may be eligible to participate in this trial based on your search.Apply for study
    Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

    References

    Clinical Trials Gov: Study of PF-07248144 in Advanced or Metastatic Solid Tumors

    Other trails to consider

    Top searched conditions